Eine Studie zur Verträglichkeit, Sicherheit und Wirksamkeit von Asciminib bei Patienten mit Philadelphia-Chromosom-positiver chronischer myeloischer Leukämie in der chronischen Phase in Deutschland (ASC2ADHERE)
Eine nicht-interventionelle Studie zur Verträglichkeit, Sicherheit und Wirksamkeit von Asciminib bei neu diagnostizierten und vorbehandelten Patienten mit Philadelphia-Chromosom-positiver chronischer myeloischer Leukämie in der chronischen Phase in Deutschland – die ASC2ADHERE-Studie
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
- E-Mail: novartis.email@novartis.com
Studieren Sie die Kontaktsicherung
- Name: Novartis Pharmaceuticals
Studienorte
-
-
-
Amberg, Deutschland, 92224
- Rekrutierung
- Novartis Investigative Site
-
Bad Friedrichshall, Deutschland, 74177
- Rekrutierung
- Novartis Investigative Site
-
Bad Liebenwerda, Deutschland, 04924
- Rekrutierung
- Novartis Investigative Site
-
Bad Saarow, Deutschland, 15526
- Rekrutierung
- Novartis Investigative Site
-
Berlin, Deutschland, 10437
- Rekrutierung
- Novartis Investigative Site
-
Berlin, Deutschland, 10365
- Rekrutierung
- Novartis Investigative Site
-
Berlin, Deutschland, 12552
- Rekrutierung
- Novartis Investigative Site
-
Berlin, Deutschland, 10559
- Rekrutierung
- Novartis Investigative Site
-
Berlin, Deutschland, 12487
- Rekrutierung
- Novartis Investigative Site
-
Bremerhaven, Deutschland, 27568
- Rekrutierung
- Novartis Investigative Site
-
Buchholz Nordheide, Deutschland, 21244
- Rekrutierung
- Novartis Investigative Site
-
Cottbus, Deutschland, 03046
- Rekrutierung
- Novartis Investigative Site
-
Deggendorf, Deutschland, 94469
- Rekrutierung
- Novartis Investigative Site
-
Detmold, Deutschland, 32756
- Rekrutierung
- Novartis Investigative Site
-
Dorfen, Deutschland, 84405
- Rekrutierung
- Novartis Investigative Site
-
Dortmund, Deutschland, 44263
- Rekrutierung
- Novartis Investigative Site
-
Dresden, Deutschland, 01307
- Rekrutierung
- Novartis Investigative Site
-
Dresden, Deutschland, 01127
- Rekrutierung
- Novartis Investigative Site
-
Düren, Deutschland, 52353
- Rekrutierung
- Novartis Investigative Site
-
Erfurt, Deutschland, 99085
- Rekrutierung
- Novartis Investigative Site
-
Erfurt, Deutschland, 99084
- Rekrutierung
- Novartis Investigative Site
-
Eschweiler, Deutschland, 52249
- Rekrutierung
- Novartis Investigative Site
-
Göttingen, Deutschland, 37073
- Rekrutierung
- Novartis Investigative Site
-
Hanover, Deutschland, 30161
- Rekrutierung
- Novartis Investigative Site
-
Hanover, Deutschland, 30625
- Rekrutierung
- Novartis Investigative Site
-
Hildesheim, Deutschland, 31135
- Rekrutierung
- Novartis Investigative Site
-
Kiel, Deutschland, 24105
- Rekrutierung
- Novartis Investigative Site
-
Leipzig, Deutschland, 04103
- Rekrutierung
- Novartis Investigative Site
-
Leverkusen, Deutschland, 51375
- Rekrutierung
- Novartis Investigative Site
-
Mutlangen, Deutschland, 73557
- Rekrutierung
- Novartis Investigative Site
-
Naunhof, Deutschland, 04683
- Rekrutierung
- Novartis Investigative Site
-
Neuss, Deutschland, 41462
- Rekrutierung
- Novartis Investigative Site
-
Offenburg, Deutschland, 77654
- Rekrutierung
- Novartis Investigative Site
-
Oldenburg, Deutschland, 26121
- Rekrutierung
- Novartis Investigative Site
-
Parchim, Deutschland, 19370
- Rekrutierung
- Novartis Investigative Site
-
Potsdam, Deutschland, 14467
- Rekrutierung
- Novartis Investigative Site
-
Potsdam, Deutschland, 14482
- Rekrutierung
- Novartis Investigative Site
-
Schorndorf, Deutschland, 73614
- Rekrutierung
- Novartis Investigative Site
-
Schwetzingen, Deutschland, 68723
- Rekrutierung
- Novartis Investigative Site
-
Soest, Deutschland, 59494
- Rekrutierung
- Novartis Investigative Site
-
Stade, Deutschland, 21680
- Rekrutierung
- Novartis Investigative Site
-
Torgau, Deutschland, 04860
- Rekrutierung
- Novartis Investigative Site
-
Ulm, Deutschland, 89081
- Rekrutierung
- Novartis Investigative Site
-
Wetzlar, Deutschland, 35578
- Rekrutierung
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Baden-Baden, Baden-Wurttemberg, Deutschland, 76532
- Rekrutierung
- Novartis Investigative Site
-
Heidenheim, Baden-Wurttemberg, Deutschland, 89522
- Rekrutierung
- Novartis Investigative Site
-
Schwäbisch Hall, Baden-Wurttemberg, Deutschland, 74523
- Rekrutierung
- Novartis Investigative Site
-
Winnenden, Baden-Wurttemberg, Deutschland, 71364
- Rekrutierung
- Novartis Investigative Site
-
-
Bavaria
-
Aschaffenburg, Bavaria, Deutschland, 63739
- Rekrutierung
- Novartis Investigative Site
-
Augsburg, Bavaria, Deutschland, 86152
- Rekrutierung
- Novartis Investigative Site
-
Donauwörth, Bavaria, Deutschland, 86609
- Rekrutierung
- Novartis Investigative Site
-
Herrsching am Ammersee, Bavaria, Deutschland, 82211
- Rekrutierung
- Novartis Investigative Site
-
Kempten (Allgäu), Bavaria, Deutschland, 87439
- Rekrutierung
- Novartis Investigative Site
-
Landsberg am Lech, Bavaria, Deutschland, 86899
- Rekrutierung
- Novartis Investigative Site
-
Munich, Bavaria, Deutschland, 81241
- Rekrutierung
- Novartis Investigative Site
-
Munich, Bavaria, Deutschland, 81377
- Rekrutierung
- Novartis Investigative Site
-
Regensburg, Bavaria, Deutschland, 93053
- Rekrutierung
- Novartis Investigative Site
-
-
Free Hanseatic City of Bremen
-
Bremerhaven, Free Hanseatic City of Bremen, Deutschland, 27576
- Rekrutierung
- Novartis Investigative Site
-
-
Hesse
-
Kassel, Hesse, Deutschland, 34125
- Rekrutierung
- Novartis Investigative Site
-
Offenbach, Hesse, Deutschland, 63065
- Rekrutierung
- Novartis Investigative Site
-
-
Lower Saxony
-
Goslar, Lower Saxony, Deutschland, 38642
- Rekrutierung
- Novartis Investigative Site
-
Rotenburg (Wümme), Lower Saxony, Deutschland, 27356
- Rekrutierung
- Novartis Investigative Site
-
Twistringen, Lower Saxony, Deutschland, 27239
- Rekrutierung
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Deutschland, 50674
- Rekrutierung
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Deutschland, 50677
- Rekrutierung
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Deutschland, 51103
- Rekrutierung
- Novartis Investigative Site
-
Solingen, North Rhine-Westphalia, Deutschland, 42653
- Rekrutierung
- Novartis Investigative Site
-
Wesel, North Rhine-Westphalia, Deutschland, 46483
- Rekrutierung
- Novartis Investigative Site
-
-
Saxony
-
Zittau, Saxony, Deutschland, 02763
- Rekrutierung
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Deutschland, 06110
- Rekrutierung
- Novartis Investigative Site
-
Merseburg, Saxony-Anhalt, Deutschland, 06217
- Rekrutierung
- Novartis Investigative Site
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, Deutschland, 23758
- Rekrutierung
- Novartis Investigative Site
-
-
Thuringia
-
Altenburg, Thuringia, Deutschland, 04600
- Rekrutierung
- Novartis Investigative Site
-
Saalfeld, Thuringia, Deutschland, 07318
- Rekrutierung
- Novartis Investigative Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.
Beschreibung
Inclusion criteria:
- Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
- Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
- Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
- Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
- Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.
Exclusion criteria:
-
Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:
-
In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).
-
In second-line treatment:
- known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
- presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
-
-
Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.
-
Patients currently participating in an interventional clinical trial.
-
Patients unable or unwilling to provide written informed consent.
-
Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.
-
Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.
-
The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
Asciminib Cohort
Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib. |
|
Imatinib Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment. |
|
Second-generation TKI Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Zeitfenster: Month 12
|
MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS). |
Month 12
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Prozentsatz der Patienten nach Grund für die vom behandelnden Arzt dokumentierte Entscheidung zur TKI-Therapie
Zeitfenster: Baseline
|
Baseline
|
|
|
Anteil der Patienten mit Dosisreduktion nach Grund für die Dosisreduktion
Zeitfenster: 3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
|
|
<string>Anteil der Patienten mit Behandlungsunterbrechung nach Grund der Unterbrechung</string>
Zeitfenster: 3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
|
|
Prozentsatz der Patienten, die die Behandlung abbrachen, nach Grund für den Abbruch
Zeitfenster: 3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
|
|
Zeit bis zum Behandlungsabbruch
Zeitfenster: 3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
|
|
Zeit bis zum Behandlungsabbruch
Zeitfenster: 3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
|
|
Time to Dose Reduction
Zeitfenster: 3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
|
|
Zeit bis zum Behandlungsabbruch aufgrund unerwünschter Ereignisse
Zeitfenster: 3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
3, 6, 9, 12, 15, 18, 21 und 24 Monate
|
|
|
Percentage of Patients by Clinical Characteristic
Zeitfenster: Baseline
|
Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status. |
Baseline
|
|
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Zeitfenster: Month 3
|
EMR is defined as BCR::ABL1 ≤10% IS. |
Month 3
|
|
Percentage of Patients With Molecular Response 2 (MR2)
Zeitfenster: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
MR2 is defined as BCR::ABL1 ≤1% IS. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With MMR
Zeitfenster: 3, 6, 9, 15, 18, 21, and 24 months
|
MMR is defined as BCR::ABL1 ≤0.1% IS. |
3, 6, 9, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.0
Zeitfenster: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.5
Zeitfenster: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR5
Zeitfenster: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Medication Adherence Report Scale (MARS-5) Score
Zeitfenster: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Zeitfenster: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Zeitfenster: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30. The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100. A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Zeitfenster: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen
- Chronische Erkrankung
- Krankheitsattribute
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Leukämie, Myeloid
- Erkrankungen des Knochenmarks
- Leukämie
- Myeloproliferative Erkrankungen
- Pathologische Zustände, Anzeichen und Symptome
- Hämische und lymphatische Krankheiten
- Leukämie, myeloische, chronische, BCR-ABL-positiv
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CABL001J1DE02
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .